About BerGenBio

Company Description

BerGenBio is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases, including cancer and severe respiratory infections.

AXL: a promising target to treat life-threatening diseases
The tyrosine kinase target AXL is known to play an important role in both the innate and adaptive immune systems, BerGenBio is developing two highly selective AXL inhibitors bemcentinib and tilvestamab.

Business model: R&D excellence and strategic partnerships
BerGenBio is leveraging its solid leadership position in understanding the role of AXL and related kinase signalling in diseases of high unmet need to develop a diversified pipeline of selective AXL inhibitors.

Year founded

2007

Served area

Worldwide

Shareholder information

Shares outstanding

88,660,532

IPO

April 7, 2017

Stock exchange(s)

Euronext Oslo

Contact

Newsletter

Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.